---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Use of the CD47 Phosphorodiamidate Morpholino Oligomers for the Treatment, Prevention, and Diagnosis of Solid Tumors"
date: 2026-02-05 19:08:01 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2019-28355
original_published: 2020-01-03 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Use of the CD47 Phosphorodiamidate Morpholino Oligomers for the Treatment, Prevention, and Diagnosis of Solid Tumors

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 03, 2020 00:00 UTC
**Document Number:** 2019-28355

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Morphiex Biotherapeutics ("Morphiex") located in Boston, MA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/03/2019-28355/prospective-grant-of-an-exclusive-patent-license-use-of-the-cd47-phosphorodiamidate-morpholino)
- API: https://www.federalregister.gov/api/v1/documents/2019-28355

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
